NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology, Inc. (NAUT) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (F). The rating has held at C for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | F (0.1) | C+ (2.5) | B- (3.0) | B+ (3.5) | C+ (2.6) | C (2.3) |
| 2026-11-06 | F (0.2) | C+ (2.5) | B- (3.0) | B (3.2) | C+ (2.7) | C (2.3) |
| 2026-10-30 | F (0.0) | C+ (2.5) | C+ (2.8) | C+ (2.8) | C+ (2.7) | C (2.2) |
| 2026-10-23 | F (0.0) | C+ (2.5) | C+ (2.8) | C (2.2) | C+ (2.6) | C- (2.0) |
| 2026-10-16 | F (0.0) | C+ (2.5) | C+ (2.8) | C- (1.9) | C+ (2.6) | C- (2.0) |